PMID- 28870867
OWN - NLM
STAT- MEDLINE
DCOM- 20171213
LR  - 20180206
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 183
DP  - 2017 Oct
TI  - Hematologic neoplasms: Dendritic cells vaccines in motion.
PG  - 181-190
LID - S1521-6616(17)30139-0 [pii]
LID - 10.1016/j.clim.2017.08.016 [doi]
AB  - Dendritic cells (DCs) are bone-marrow-derived immune cells accounted for a key 
      role in cancer vaccination as potent antigen-presenting cells within the immune 
      system. Cancer microenvironment can modulate DCs maturation resulting in their 
      accumulation into functional states associated with a reduced antitumor immune 
      response. In this regard, a successful cancer vaccine needs to mount a potent 
      antitumor immune response able to overcome the immunosuppressive tumor milieu. As 
      a consequence, DCs-based approaches are a safe and promising strategy for 
      improving the therapeutic efficacy in hematological malignancies, particularly in 
      combinations with additional treatments. This review summarizes the most 
      significant evidence about the immunotherapeutic strategies performed to target 
      hematologic neoplasms including the tumoral associated antigens (TAA) pulsed on 
      DCs, whole tumor cell vaccines or leukemia-derived DCs.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Galati, Domenico
AU  - Galati D
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, 
      National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 
      49, 80131 Naples, Italy. Electronic address: d.galati@istitutotumori.na.it.
FAU - Zanotta, Serena
AU  - Zanotta S
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, 
      National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 
      49, 80131 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170912
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Hematologic Neoplasms/*prevention & control
MH  - Humans
OTO - NOTNLM
OT  - Cancer vaccination
OT  - DC vaccine
OT  - Dendritic cells
OT  - Hematologic neoplasms
OT  - Hematological malignancies
OT  - Immunotherapy
EDAT- 2017/09/06 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/09/06 06:00
PHST- 2017/02/27 00:00 [received]
PHST- 2017/07/28 00:00 [revised]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/09/06 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
PHST- 2017/09/06 06:00 [entrez]
AID - S1521-6616(17)30139-0 [pii]
AID - 10.1016/j.clim.2017.08.016 [doi]
PST - ppublish
SO  - Clin Immunol. 2017 Oct;183:181-190. doi: 10.1016/j.clim.2017.08.016. Epub 2017 
      Sep 12.